UNSPSC 51161556: Tomelukast

This classification denotes an anti-asthmatic agent with the molecular formula C16H22N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59762X5CLS, chemically known as ly-171,883 but generally known as tomelukast, which bears US NIH Compound Identifier 3969. European Medicines Agency schedules Tomelukast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11184MIG. The term TOMELUKAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29).

UNSPSC 51161556 Tomelukast is a Commodity code covering individual pharmaceutical products supplied through state and local cooperative purchasing agreements. State and local governments procure tomelukast and similar generic pharmaceuticals through multistate cooperative frameworks that bundle procurement across participating jurisdictions, negotiating volume pricing with manufacturers and distributing products through authorized pharmaceutical wholesalers to hospitals, clinics, and other government-run healthcare facilities. The issuing bodies are state departments of administration and multistate purchasing alliances; individual states, counties, school districts, and healthcare systems access these contracts as members of the cooperative rather than as direct procurement initiators.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, including tomelukast, for distribution across participating state and local government facilities in Minnesota and Oregon. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), comply with cGMP and DSCSA requirements, and submit detailed pricing in flat price, net price (NF30/NF60/NF90), or WAC-minus formats. Evaluation weighs price competitiveness at 75 percent, with the remaining 25 percent split among fixed pricing submission (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). The contract term is two years for new vendors with optional MMCAP extensions, or through June 30, 2028 for incumbents, with products required to be available in the marketplace by May 15, 2026 and awarded agreements effective July 1, 2026. No specific award value or budget range was disclosed, and no set-aside designations were identified in available documentation.